Skip to main content
Erschienen in: Clinical Rheumatology 4/2019

15.11.2018 | Original Article

Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis

verfasst von: Wenjia Sun, Lizhen Tian, Lichun Jiang, Songzhao Zhang, Meiju Zhou, Jianing Zhu, Jing Xue

Erschienen in: Clinical Rheumatology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

To determine the serum levels of Dickkopf-1 (DKK-1) and sclerostin, as well as their correlations with the structural damage assessed by modified stoke ankylosing spondylitis spine score (mSASSS) and the disease activity evaluated by ankylosing spondylitis disease activity score (ASDAS) in patients with ankylosing spondylitis (AS).

Methods

Eighty-eight AS patients, 26 rheumatoid arthritis (RA) patients, and 26 age- and gender-matched healthy controls (HC) were collected from rheumatic clinic of the Second Affiliated Hospital of Zhejiang University, School of Medicine, between March 2015 and July 2015. Demographic data, parameters of ASDAS, and image evaluations of spine (i.e., mSASSS) were collected. The serum levels of DKK-1 and sclerostin were measured using commercially available ELISA kits.

Results

Both DKK-1 and sclerostin were significantly higher in the AS patients than in the controls (1855 ± 84.58 vs. 1406 ± 99.76 pg/ml and 106 ± 6.75 vs. 62.78 ± 6.39 pmol/l, respectively, P < 0.05). The correlation analysis suggested a negative correlation between serum sclerostin and mSASSS (P = 0.019, r2 = 0.062). DKK-1 had a trend of positive correlation with mSASSS, but was not statistically significant (P > 0.05). There was no association between the serum levels of DKK-1 or sclerostin and disease activity assessed by ASDAS (P > 0.05). DKK-1 and sclerostin had a negative correlation (P = 0.013, r2 = 0.07).

Conclusion

In the present study, the expressions of serum DKK-1 and sclerostin were independent of disease activity. Sclerostin was negatively correlated with the mSASSS, which suggests that sclerostin may be a potential marker indicating the spine ossification process in AS. The specific mechanism remains to be investigated.
Literatur
1.
Zurück zum Zitat Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369:1379–1390CrossRef Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369:1379–1390CrossRef
3.
Zurück zum Zitat Smith JA (2015) Update on ankylosing spondylitis: current concepts in pathogenesis. Curr Allergy Asthma Rep 15:489CrossRefPubMed Smith JA (2015) Update on ankylosing spondylitis: current concepts in pathogenesis. Curr Allergy Asthma Rep 15:489CrossRefPubMed
4.
5.
Zurück zum Zitat Tsui FW, Tsui HW, Las Heras F, Pritzker KP, Inman RD (2014) Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis 73:1873–1879CrossRefPubMed Tsui FW, Tsui HW, Las Heras F, Pritzker KP, Inman RD (2014) Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis 73:1873–1879CrossRefPubMed
8.
Zurück zum Zitat Xie W, Zhou L, Li S, Hui T, Chen D (2016) Wnt/β-catenin signaling plays a key role in the development of spondyloarthritis. Ann N Y Acad Sci 1364:25–31CrossRefPubMed Xie W, Zhou L, Li S, Hui T, Chen D (2016) Wnt/β-catenin signaling plays a key role in the development of spondyloarthritis. Ann N Y Acad Sci 1364:25–31CrossRefPubMed
9.
Zurück zum Zitat Klavdianou K, Liossis SN, Sakkas L, Daoussis D (2017) The role of Dickkopf-1 in joint remodeling and fibrosis: a link connecting spondyloarthropathies and scleroderma? Semin Arthritis Rheum 46:430–438CrossRefPubMed Klavdianou K, Liossis SN, Sakkas L, Daoussis D (2017) The role of Dickkopf-1 in joint remodeling and fibrosis: a link connecting spondyloarthropathies and scleroderma? Semin Arthritis Rheum 46:430–438CrossRefPubMed
10.
Zurück zum Zitat Wu M, Chen M, Ma Y, Yang J, Han R, Yuan Y, Hu X, Wang M, Zhang X, Xu S, Liu R, Jiang G, Xu J, Shuai Z, Zou Y, Pan G, Pan F (2018) Dickkopf-1 in ankylosing spondylitis: review and meta-analysis. Clin Chim Acta 481:177–183CrossRefPubMed Wu M, Chen M, Ma Y, Yang J, Han R, Yuan Y, Hu X, Wang M, Zhang X, Xu S, Liu R, Jiang G, Xu J, Shuai Z, Zou Y, Pan G, Pan F (2018) Dickkopf-1 in ankylosing spondylitis: review and meta-analysis. Clin Chim Acta 481:177–183CrossRefPubMed
11.
Zurück zum Zitat Daoussis D, Andonopoulos AP, Liossis SN (2010) Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis. Semin Arthritis Rheum 39:369–383CrossRefPubMed Daoussis D, Andonopoulos AP, Liossis SN (2010) Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis. Semin Arthritis Rheum 39:369–383CrossRefPubMed
12.
Zurück zum Zitat Zhang L, Ouyang H, Xie Z, Liang ZH, Wu XW (2016) Serum DKK-1 level in the development of ankylosing spondylitis and rheumatic arthritis: a meta-analysis. Exp Mol Med 48:e228CrossRefPubMedPubMedCentral Zhang L, Ouyang H, Xie Z, Liang ZH, Wu XW (2016) Serum DKK-1 level in the development of ankylosing spondylitis and rheumatic arthritis: a meta-analysis. Exp Mol Med 48:e228CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Niu CC, Lin SS, Yuan LJ, Chen LH, Yang CY, Chung AN, Lu ML, Tsai TT, Lai PL, Chen WJ (2017) Correlation of blood bone turnover biomarkers and Wnt signaling antagonists with AS, DISH, OPLL, and OYL. BMC Musculoskelet Disord 18:61CrossRefPubMedPubMedCentral Niu CC, Lin SS, Yuan LJ, Chen LH, Yang CY, Chung AN, Lu ML, Tsai TT, Lai PL, Chen WJ (2017) Correlation of blood bone turnover biomarkers and Wnt signaling antagonists with AS, DISH, OPLL, and OYL. BMC Musculoskelet Disord 18:61CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Wanders AJ, Landewé RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H et al (2004) What is the most appropriate radiologic scoring method for ankylosing ? Arthritis Rheum 50:2622–2632CrossRefPubMed Wanders AJ, Landewé RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H et al (2004) What is the most appropriate radiologic scoring method for ankylosing ? Arthritis Rheum 50:2622–2632CrossRefPubMed
15.
16.
Zurück zum Zitat Liang H, Li WR, Zhang H, Tian X, Wei W, Wang CM (2015) Concurrent intervention with exercises and stabilized tumor necrosis factor inhibitor therapy reduced the disease activity in patients with ankylosing spondylitis. Medicine (Baltimore) 94:e2254CrossRef Liang H, Li WR, Zhang H, Tian X, Wei W, Wang CM (2015) Concurrent intervention with exercises and stabilized tumor necrosis factor inhibitor therapy reduced the disease activity in patients with ankylosing spondylitis. Medicine (Baltimore) 94:e2254CrossRef
17.
Zurück zum Zitat Osman MS, Maksymowych WP (2017) An update on the use of tumor necrosis factor alpha inhibitors in the treatment of ankylosing spondylitis. Expert Rev Clin Immunol 13:125–131CrossRefPubMed Osman MS, Maksymowych WP (2017) An update on the use of tumor necrosis factor alpha inhibitors in the treatment of ankylosing spondylitis. Expert Rev Clin Immunol 13:125–131CrossRefPubMed
18.
Zurück zum Zitat Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards W, Kronke G, Schett G (2010) Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 69:592–597CrossRefPubMed Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards W, Kronke G, Schett G (2010) Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 69:592–597CrossRefPubMed
19.
Zurück zum Zitat Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, Baraliakos X, Listing J, Rudwaleit M, Schett G, Sieper J (2012) High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 71:572–574CrossRefPubMed Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, Baraliakos X, Listing J, Rudwaleit M, Schett G, Sieper J (2012) High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 71:572–574CrossRefPubMed
20.
Zurück zum Zitat Sakellariou GT, Iliopoulos A, Konsta M, Kenanidis E, Potoupnis M, Tsiridis E, Gavana E, Sayegh FE (2017) Serum levels of DKK-1, sclerostin and VEGF in patients with ankylosing spondylitis and their association with smoking, and clinical, inflammatory and radiographic parameters. Jt Bone Spine 84:309–315CrossRef Sakellariou GT, Iliopoulos A, Konsta M, Kenanidis E, Potoupnis M, Tsiridis E, Gavana E, Sayegh FE (2017) Serum levels of DKK-1, sclerostin and VEGF in patients with ankylosing spondylitis and their association with smoking, and clinical, inflammatory and radiographic parameters. Jt Bone Spine 84:309–315CrossRef
21.
Zurück zum Zitat Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou MEE et al (2010) Evidence that DKK-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 62:150–158CrossRefPubMed Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou MEE et al (2010) Evidence that DKK-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 62:150–158CrossRefPubMed
22.
Zurück zum Zitat Korkosz M, Gąsowski J, Leszczyński P, Pawlak-Buś K, Jeka S, Kucharska E, Grodzicki T (2013) High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage. BMC Musculoskelet Disord 14:99–104CrossRefPubMedPubMedCentral Korkosz M, Gąsowski J, Leszczyński P, Pawlak-Buś K, Jeka S, Kucharska E, Grodzicki T (2013) High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage. BMC Musculoskelet Disord 14:99–104CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Ustun N, Tok F, Kalyoncu U, Motor S, Yuksel R, Yagiz AE, Guler H, Turhanoglu AD (2014) Sclerostin and Dkk-1 in patients with ankylosing spondylitis. Acta Reumatol Port 39:146–151PubMed Ustun N, Tok F, Kalyoncu U, Motor S, Yuksel R, Yagiz AE, Guler H, Turhanoglu AD (2014) Sclerostin and Dkk-1 in patients with ankylosing spondylitis. Acta Reumatol Port 39:146–151PubMed
24.
Zurück zum Zitat Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, Kim HA, Choi HJ, Park W (2012) Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int 32:2523–2527CrossRefPubMed Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, Kim HA, Choi HJ, Park W (2012) Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int 32:2523–2527CrossRefPubMed
25.
Zurück zum Zitat Klavdianou K, Liossis SN, Papachristou DJ, Theocharis G, Sirinian C, Kottorou A, Filippopoulou A, Andonopoulos AP, Daoussis D (2016) Decreased serotonin levels and serotonin-mediated osteoblastic inhibitory signaling in patients with ankylosing spondylitis. J Bone Miner Res 31:630–639CrossRefPubMed Klavdianou K, Liossis SN, Papachristou DJ, Theocharis G, Sirinian C, Kottorou A, Filippopoulou A, Andonopoulos AP, Daoussis D (2016) Decreased serotonin levels and serotonin-mediated osteoblastic inhibitory signaling in patients with ankylosing spondylitis. J Bone Miner Res 31:630–639CrossRefPubMed
26.
Zurück zum Zitat Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33:747–783CrossRef Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33:747–783CrossRef
27.
Zurück zum Zitat Yucong Z, Lu L, Shengfa L, Yongliang Y, Ruguo S, Yikai L (2014) Serum functional dickkopf-1 levels are inversely correlated with radiographic severity of ankylosing spondylitis. Clin Lab 60:1527–1531CrossRefPubMed Yucong Z, Lu L, Shengfa L, Yongliang Y, Ruguo S, Yikai L (2014) Serum functional dickkopf-1 levels are inversely correlated with radiographic severity of ankylosing spondylitis. Clin Lab 60:1527–1531CrossRefPubMed
28.
Zurück zum Zitat Costa AG, Cremers S, Bilezikian JP (2017) Sclerostin measurement in human disease: validity and current limitations. Bone 96:24–28CrossRef Costa AG, Cremers S, Bilezikian JP (2017) Sclerostin measurement in human disease: validity and current limitations. Bone 96:24–28CrossRef
29.
Zurück zum Zitat Sellas I, Fernandez A, Juanola Roura X, Alonso Ruiz A, Rosas J, Medina Luezas J, Collantes Estevez E et al (2017) Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study). Rheumatol Int 37:1817–1823CrossRef Sellas I, Fernandez A, Juanola Roura X, Alonso Ruiz A, Rosas J, Medina Luezas J, Collantes Estevez E et al (2017) Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study). Rheumatol Int 37:1817–1823CrossRef
30.
Zurück zum Zitat Machado PM, Landewé R, Heijde DV, Assessment of SpondyloArthritis international Society (ASAS) (2018) Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis 77:1539–1540PubMed Machado PM, Landewé R, Heijde DV, Assessment of SpondyloArthritis international Society (ASAS) (2018) Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis 77:1539–1540PubMed
31.
Zurück zum Zitat Rossini M, Viapiana O, Idolazzi L, Ghellere F, Fracassi E, Troplini S, Povino MR, Kunnathully V, Adami S, Gatti D (2016) Higher level of Dickkopf-1 is associated with low bone mineral density and higher prevalence of vertebral fractures in patients with ankylosing spondylitis. Calcif Tissue Int 98:438–445CrossRefPubMed Rossini M, Viapiana O, Idolazzi L, Ghellere F, Fracassi E, Troplini S, Povino MR, Kunnathully V, Adami S, Gatti D (2016) Higher level of Dickkopf-1 is associated with low bone mineral density and higher prevalence of vertebral fractures in patients with ankylosing spondylitis. Calcif Tissue Int 98:438–445CrossRefPubMed
32.
Zurück zum Zitat Muntean L, Lungu A, Gheorghe SR, Valeanu M, Craciun AM, Felea I et al (2016) Elevated serum levels of Sclerostin are associated with high disease activity and functional impairment in patients with axial spondyloarthritis. Clin Lab 62:589–597CrossRefPubMed Muntean L, Lungu A, Gheorghe SR, Valeanu M, Craciun AM, Felea I et al (2016) Elevated serum levels of Sclerostin are associated with high disease activity and functional impairment in patients with axial spondyloarthritis. Clin Lab 62:589–597CrossRefPubMed
33.
Zurück zum Zitat Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60:3257–3262CrossRefPubMed Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60:3257–3262CrossRefPubMed
Metadaten
Titel
Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis
verfasst von
Wenjia Sun
Lizhen Tian
Lichun Jiang
Songzhao Zhang
Meiju Zhou
Jianing Zhu
Jing Xue
Publikationsdatum
15.11.2018
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 4/2019
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4356-z

Weitere Artikel der Ausgabe 4/2019

Clinical Rheumatology 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.